International journal of pharmaceutics · 2026
Development of a thermosensitive hydrogel containing liposomes for sustained dexamethasone delivery in sensorineural hearing loss.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chloé Gauthy, Nicholas Cole, Enes Spahic, Raphaël Closset, Erika Hendrickx, Louise Conrard, Yasmina Bodadi, Hugo Magdalena Segura, Valentin Tallandier, Pierre-Bernard Van Lerberghe, Laurence Collard, Noémie Penoy, Frédéric Boschini, Brigitte Evrard, Laurence Delacroix, Brigitte Malgrange, Géraldine Piel
Аннотация
Dexamethasone-loaded liposomes composed of DSPC/Chol/PEG (85/10/5 mol%) and dispersed in a 16.25% Poloxamer 407 (P407) hydrogel were developed as a local therapeutic strategy for sound trauma-induced sensorineural hearing loss (SNHL). Physicochemical and rheological characterization demonstrated that the formulation remains injectable at room temperature and undergoes rapid in situ gelation within 8.0 ± 3.8 min in the middle ear cavity at 37°C. Incorporation of liposomes into the 16.25% P407 hydrogel significantly prolonged the in vitro release of encapsulated dexamethasone compared to the free drug solution. Cryogenic transmission electron microscopy (cryo-TEM) revealed multilamellar and multivesicular liposomal vesicles, consistent with sustained release behavior. The formulation was well tolerated by HEI-OC1 cells and cochlear explants and conferred a significant otoprotective effect, as evidenced by preservation of synaptic surface area following kainic acid-induced excitotoxic injury.